Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

(2014) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

(2012) J Alexandre et al.   BRITISH JOURNAL OF CANCER

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)

(2011) A. Lortholary et al.   ANNALS OF ONCOLOGY

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study

(2011) Thomas J. Herzog et al.   GYNECOLOGIC ONCOLOGY

Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial

(2011) Leslie M. Randall et al.   GYNECOLOGIC ONCOLOGY

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy

(2008) Nilofer S. Azad et al.   CANCER